A five-year-old, female spayed, crossbreed dog was presented for lethargy, fever, hyporexia and right hindlimb lameness of two weeks’ duration. Examination revealed an intermittent weightbearing right hindlimb lameness with delayed proprioceptive reflexes. When the right hindlimb was placed, weightbearing was through the dorsal pes. The other limbs were neurologically normal. The neurological deficits localised to L6–S2. CT and myelogram revealed focal nerve root enlargement with contrast enhancement of L7–S1 nerve roots. Neospora caninum neuritis was diagnosed by rising serum titres, along with a neutrophilic pleocytosis on cerebrospinal fluid. The dog showed clinical improvement with prednisone, clindamycin and trimethoprim/sulfadiazine but relapsed six months after cessation of treatment with similar presentation. The same treatment was initiated, and a positive response was seen again. There is only one other case of focal cauda equina neuritis secondary to Neospora reported in the literature and the response to treatment is not well documented.

A 12-year-old, female spayed crossbred dog was presented for traumatic injuries sustained after being hit by a car. The dog was non-ambulatory with a right-sided head tilt on presentation, neurological deficits and signs of external trauma centred on the head. A trauma computed tomography was performed which revealed an atlanto-occipital luxation with narrowing of the vertebral canal. This was treated successfully via closed reduction and confirmed with a repeat computed tomography scan. The dog recovered well following the atlanto-occipital luxation reduction, and was ambulatory the day after the reduction, and neurological signs resolved within 2 days.

The objective of this research was to evaluate comparative pharmacokinetics of doramectin in alpacas, after subcutaneous administration of 0.2 mg/kg dose. Six healthy adult alpacas, mean age of 5 years ± 1, (three female and three gelded males) of mean bodyweight of 62 kg ± 16 kg with an average body condition scored 2.8 ± 1 out of five, were used in this study. Serial blood samples were collected from the jugular vein before the administration until day 21 afterwards to establish the pharmacokinetics of doramectin after its subcutaneous administration at 0.2 mg/kg dose. The blood samples were analysed using high‐performance liquid chromatography (HPLC), fluorescence detection method with precolumn derivatisation, validated for alpacas. The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half‐life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days). The results of this study showed that the Cmax and AUC were much lower than in cattle and sheep at the same dosage. Tmax remained similar to cattle and sheep. This study presents valuable information about pharmacokinetics of doramectin in alpacas, which can be utilised in its future efficacy studies.